Ghisallo Capital Management LLC Has $54.54 Million Position in Kenvue Inc. (NYSE:KVUE)

Ghisallo Capital Management LLC grew its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 200.0% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 3,000,000 shares of the company’s stock after purchasing an additional 2,000,000 shares during the period. Kenvue comprises approximately 3.5% of Ghisallo Capital Management LLC’s portfolio, making the stock its 7th biggest holding. Ghisallo Capital Management LLC’s holdings in Kenvue were worth $54,540,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Manchester Capital Management LLC boosted its holdings in shares of Kenvue by 80.8% in the first quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock worth $25,000 after buying an additional 530 shares during the period. Mather Group LLC. acquired a new position in shares of Kenvue in the first quarter worth about $28,000. Riverview Trust Co acquired a new position in shares of Kenvue in the first quarter worth about $33,000. MV Capital Management Inc. boosted its holdings in shares of Kenvue by 71.2% in the first quarter. MV Capital Management Inc. now owns 1,544 shares of the company’s stock worth $33,000 after buying an additional 642 shares during the period. Finally, Salomon & Ludwin LLC acquired a new position in shares of Kenvue in the first quarter worth about $33,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Down 1.5 %

Shares of NYSE:KVUE opened at $22.79 on Wednesday. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $23.55. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.68 and a current ratio of 0.99. The company’s fifty day moving average is $21.60 and its 200-day moving average is $20.11. The company has a market capitalization of $43.63 billion, a PE ratio of 29.21, a P/E/G ratio of 2.92 and a beta of 1.40.

Kenvue (NYSE:KVUE) last issued its earnings results on Tuesday, August 6th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.28 by $0.04. Kenvue had a net margin of 7.23% and a return on equity of 21.80%. The company had revenue of $4 billion for the quarter, compared to the consensus estimate of $3.93 billion. During the same quarter in the previous year, the company earned $0.32 EPS. The firm’s revenue for the quarter was down .3% compared to the same quarter last year. Equities research analysts predict that Kenvue Inc. will post 1.08 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, August 28th. Investors of record on Wednesday, August 14th were issued a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.60%. This is a boost from Kenvue’s previous quarterly dividend of $0.20. The ex-dividend date was Wednesday, August 14th. Kenvue’s payout ratio is currently 105.13%.

Analyst Ratings Changes

KVUE has been the topic of several recent research reports. Royal Bank of Canada lowered shares of Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price objective on the stock. in a research report on Tuesday, September 24th. JPMorgan Chase & Co. raised their price objective on shares of Kenvue from $22.00 to $24.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Piper Sandler raised their price objective on shares of Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a research report on Monday, September 23rd. Citigroup dropped their price target on shares of Kenvue from $21.00 to $20.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 10th. Finally, UBS Group lifted their price target on shares of Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, Kenvue currently has an average rating of “Hold” and an average target price of $22.10.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.